(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
0.00% $ 2.39
Live Chart Being Loaded With Signals
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China...
Stats | |
---|---|
Dzisiejszy wolumen | 212.00 |
Średni wolumen | 9.00 |
Kapitalizacja rynkowa | 0.00 |
Last Dividend | $0.0297 ( 2021-09-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.604 |
ATR14 | $0 (0.00%) |
Epigenomics AG Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Epigenomics AG Finanse
Annual | 2021 |
Przychody: | $6.20M |
Zysk brutto: | $6.07M (97.81 %) |
EPS: | $-0.271 |
FY | 2021 |
Przychody: | $6.20M |
Zysk brutto: | $6.07M (97.81 %) |
EPS: | $-0.271 |
FY | 2020 |
Przychody: | $842 000 |
Zysk brutto: | $697 000 (82.78 %) |
EPS: | $-2.48 |
FY | 2019 |
Przychody: | $1.13M |
Zysk brutto: | $872 000 (77.51 %) |
EPS: | $-4.48 |
Financial Reports:
No articles found.
Epigenomics AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.833 | 2018-10-31 |
Last Dividend | $0.0297 | 2021-09-16 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $2.72 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.55 | -- |
Div. Sustainability Score | 0.458 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RTMVY | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
FABP | Ex Dividend Knight | 2023-07-31 | Quarterly | 0 | 0.00% | |
YARIY | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
LTOUF | Ex Dividend Junior | 2023-08-01 | Annually | 0 | 0.00% | |
CGXYY | Ex Dividend Junior | 2023-07-11 | Annually | 0 | 0.00% | |
SOMC | Ex Dividend Knight | 2023-07-13 | Quarterly | 0 | 0.00% | |
GLAPY | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% | |
ACCYY | Ex Dividend Knight | 2023-05-23 | Sporadic | 0 | 0.00% | |
NEFB | Ex Dividend Junior | 2023-06-29 | Semi-Annually | 0 | 0.00% | |
CNND | Ex Dividend Junior | 2023-07-27 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.391 | 1.500 | -7.83 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.0984 | 1.200 | -3.28 | -3.94 | [0 - 0.3] |
returnOnEquityTTM | -0.187 | 1.500 | -3.19 | -4.78 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 11.06 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 10.72 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 10.72 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0187 | -1.500 | 9.69 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -45.35 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.463 | 2.00 | -0.154 | -0.309 | [0 - 30] |
freeCashFlowPerShareTTM | -0.467 | 2.00 | -0.233 | -0.467 | [0 - 20] |
debtEquityRatioTTM | 0.0208 | -1.500 | 9.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.978 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.380 | 1.000 | -9.60 | -9.60 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -9.03 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.252 | 0.800 | -1.657 | -1.325 | [0.5 - 2] |
Total Score | 0.458 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -8.20 | 1.000 | -0.929 | 0 | [1 - 100] |
returnOnEquityTTM | -0.187 | 2.50 | -2.05 | -4.78 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.467 | 2.00 | -0.156 | -0.467 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.463 | 2.00 | -0.154 | -0.309 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.463 | 1.500 | -6.42 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.669 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.63 |
Epigenomics AG
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej